【产品介绍】：

生物活性：Bromocriptine-13C,d3 is the 13C- and deuterium labeled Bromocriptine. Bromocriptine is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pKi of 8.05±0.2.
IC50 & Target：D2 Receptor
D3 Receptor
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[33].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Bromocriptine-13C,d3 相关抗体:
DRD2 Antibody
Dopamine Receptor D3 Antibody (YA1742)
DOPA Decarboxylase Antibody (YA2428)
Dopamine Receptor D1 Antibody (YA3270)
Torsin 1A Antibody (YA2935)
PITX3 Antibody (YA2974)
HMBS Antibody (YA3061)
分子量：658.61
Formula：C3113CH37D3BrN5O5
非标记 CAS：25614-03-3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (537 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Gardner B, et al. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124(5):978-84.
 [Content Brief]
[3]. Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406(1-2):33-6.
 [Content Brief]
[4]. Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4.
 [Content Brief]
[5]. Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35(1):90-7.
 [Content Brief]
[6]. Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11.
 [Content Brief]